Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics

被引:19
作者
Brisson, Diane [1 ,2 ]
Methot, Julie [1 ,2 ]
Tremblay, Karine [1 ,2 ]
Tremblay, Monique [1 ,2 ]
Perron, Patrice [1 ,2 ,3 ]
Gaudet, Daniel [1 ,2 ]
机构
[1] Univ Montreal, Dept Med, ECOGENE 21, Saguenay, PQ, Canada
[2] Chicoutimi Hosp, Lipid Clin, Saguenay, PQ, Canada
[3] Univ Sherbrooke, Dept Med, Sherbrooke, PQ J1K 2R1, Canada
基金
加拿大健康研究院;
关键词
apolipoprotein E; fibrates; genes; glycerol kinase; hypertriglyceridemia; lipoprotein lipase; LIPOPROTEIN-LIPASE GENE; APOLIPOPROTEIN-E; CARDIOVASCULAR-DISEASE; DIFFERENT ANCESTRIES; MISSENSE MUTATION; PPAR-ALPHA; CHOLESTEROL; FENOFIBRATE; DEFICIENCY; METABOLISM;
D O I
10.1097/FPC.0b013e328340095e
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Hypertriglyceridemia is a frequent and heterogeneous clinical trait, which modulates the risk of disease. Fibrates constitute an effective class of triglyceride-lowering agents. Objective To evaluate the effect of fibrates on fasting plasma triglycerides and other lipids levels in hypertriglyceridemia phenotypes with different genetic and clinical characteristics. Methods This study included 146 fasting adults: 15 with lactescent plasma and severe hypertriglyceridemia (triglyceride >= 10 mmol/l) and 131 with clear plasma and moderate hypertriglyceridemia (2 <= triglycerides < 10 mmol/l). Expost comparisons of the effect of fibrates on fasting triglycerides and other lipids were made using Student's paired two-tailed t-test. Results Response to these fibrates differed significantly across the studied hypertriglyceridemia subtypes: patients with severe hypertriglyceridemia because of lipoprotein lipase deficiency and those with moderate hypertriglyceridemia because of glycerol kinase deficiency did not respond at all, whereas patients with palmar xanthomas and severe or moderate hypertriglyceridemia because of apolipoprotein (apo) E resistance (type-III dysbetalipoproteinemia, most often associated with the apo E2 allele) responded significantly better (P < 0.001) than all other subtypes on several lipid fractions. Conclusion These results indicate that genetic factors known to contribute to the etiology and clinical expression of hypertriglyceridemia subtypes also modulate the response to triglyceride-lowering drugs. Pharmacogenetics and Genomics 20:742-747 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:742 / 747
页数:6
相关论文
共 28 条
[1]   Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review [J].
Abourbih, Samuel ;
Filion, Kristian B. ;
Joseph, Lawrence ;
Schiffrin, Ernesto L. ;
Rinfret, Stephane ;
Poirier, Paul ;
Pilote, Louise ;
Genest, Jacques ;
Eisenberg, Mark J. .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (10) :962.e1-962.e8
[2]   Fibrates: What have we learned in the past 40 years? [J].
Backes, James M. ;
Gibson, Cheryl A. ;
Ruisinger, Janelle E. ;
Moriarty, Patrick M. .
PHARMACOTHERAPY, 2007, 27 (03) :412-424
[3]  
BIJVOET SM, 1992, HUM MOL GENET, V1, P541
[4]   Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients [J].
Brisson, D ;
Ledoux, K ;
Bossé, Y ;
St-Pierre, J ;
Julien, P ;
Perron, P ;
Hudson, TJ ;
Vohl, MC ;
Gaudet, D .
PHARMACOGENETICS, 2002, 12 (04) :313-320
[5]  
Brunzell JD., 2001, METABOLIC MOL BASES, V8th, P2789
[6]   The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate [J].
Christidis, Dimitrios S. ;
Liberopoulos, Evangelos N. ;
Kakafika, Anna I. ;
Miltiadous, George A. ;
Cariolou, Marios ;
Ganotakis, Emmanuel S. ;
Mikhailidis, Dimitri P. ;
Elisaf, Moses S. .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2006, 11 (03) :211-221
[7]   Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia [J].
DeBruin, TWA ;
Mailly, F ;
VanBarlingen, HHJJ ;
Fisher, R ;
Cabezas, MC ;
Talmud, P ;
DallingaThie, GM ;
Humphries, SE .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1996, 26 (08) :631-639
[8]   FAT TRANSPORT IN LIPOPROTEINS - AN INTEGRATED APPROACH TO MECHANISMS AND DISORDERS (CONCLUDED) [J].
FREDRICK.DS ;
LEVY, RI ;
LEES, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (05) :273-+
[9]   Glycerol as a correlate of impaired glucose tolerance:: Dissection of a complex system by use of a simple genetic trait [J].
Gaudet, D ;
Arsenault, S ;
Pérusse, L ;
Vohl, MC ;
St-Pierre, J ;
Bergeron, J ;
Després, JP ;
Dewar, K ;
Daly, MJ ;
Hudson, T ;
Rioux, JD .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 66 (05) :1558-1568
[10]   Procedure to protect confidentiality of familial data in community genetics and genomic research [J].
Gaudet, D ;
Arsenault, S ;
Bélanger, C ;
Hudson, T ;
Perron, P ;
Bernard, M ;
Hamet, P .
CLINICAL GENETICS, 1999, 55 (04) :259-264